Sarcopenia: An Endocrine Disorder?

McKee, Alexis M.; Morley, John E.; Matsumoto, Alvin M.; Vinik, Aaron I.

doi:10.4158/ep171795.ra

Cited by 53 publications

(38 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Insufficient protein intake might result in the progression of sarcopenia or decline in muscle mass. Third, we could not evaluate biomarkers of inflammation (such as tumor necrosis factor‐α, interleukin‐6), growth factors (such as insulin‐like growth factor) or adipokines (such as leptin, adiponectin). Finally, the small sample size of participants from a single hospital in Japan was a major limitation to generalizing this result.…”

Section: Discussionmentioning

confidence: 95%

Association of accumulated advanced glycation end‐products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes

Mori

Kuroda

Ishizu

et al. 2019

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction Advanced glycation end‐products (AGEs), which are a major cause of diabetic vascular complications, accumulate in various tissues under chronic hyperglycemic conditions, as well as with aging in patients with diabetes. The loss of muscle mass and strength, so‐called sarcopenia and dynapenia, has recently been recognized as a diabetic complication. However, the influence of accumulated AGEs on muscle mass and strength remains unclear. The present study aimed to evaluate the association of sarcopenia and dynapenia with accumulated AGEs in patients with type 2 diabetes. Materials and Methods We recruited 166 patients with type 2 diabetes aged ≥30 years (mean age 63.2 ± 12.3 years; body mass index 26.3 ± 4.9 kg/m2; glycated hemoglobin 7.1 ± 1.1%). Skin autofluorescence as a marker of AGEs, limb skeletal muscle mass index, grip strength, knee extension strength and gait speed were assessed. Results Sarcopenia and dynapenia were observed in 7.2 and 13.9% of participants, respectively. Skin autofluorescence was significantly higher in patients with sarcopenia and dynapenia. Skin autofluorescence was the independent determinant for skeletal muscle mass index, grip strength, knee extension strength, sarcopenia and dynapenia. Conclusions Accumulated AGEs could contribute to reduced muscle mass and strength, leading to sarcopenia and dynapenia in patients with type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 95%

Association of accumulated advanced glycation end‐products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes

Mori

Kuroda

Ishizu

et al. 2019

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…Sarcopenia is defined as a loss of muscle mass that leads to a loss of function (60,61). Grip strength and walking speed are associated with tongue pressure and to a lesser extent jaw opening force in men (62)(63)(64)(65)(66)(67)(68).…”

Section: The Frailty Phenotype and Dysphagiamentioning

confidence: 99%

Dysphagia, Dementia and Frailty

Payne

Morley

2018

The Journal of nutrition, health and aging

Self Cite

View full text Add to dashboard Cite

“…Early recognition of frailty, using the FRAIL, and using a patient centered approach to treat the different components -fatigue, sarcopenia, polypharmacy and weight loss appears reasonable (57). Similarly screening for sarcopenia with the SARC-F (58) and providing long-term exercise therapy compensated by the medical system makes for more sense than testosterone (59,60) or antimyostatin drugs (61). While the biochemistry of senolytics is fascinating, it would seem that developing age friendly health systems with reimbursement for simple effective treatment approaches would seem a much more cost effective approach to extending a healthy life expectancy for older persons (62).…”

Section: Resultsmentioning

confidence: 99%